Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Assets (2017 - 2025)

Historic Assets for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $661.9 million.

  • Autolus Therapeutics' Assets fell 2000.54% to $661.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $661.9 million, marking a year-over-year decrease of 2000.54%. This contributed to the annual value of $782.7 million for FY2024, which is 10851.48% up from last year.
  • According to the latest figures from Q3 2025, Autolus Therapeutics' Assets is $661.9 million, which was down 2000.54% from $721.0 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Assets ranged from a high of $901.4 million in Q1 2024 and a low of $263.8 million during Q3 2022
  • For the 5-year period, Autolus Therapeutics' Assets averaged around $526.4 million, with its median value being $451.0 million (2023).
  • As far as peak fluctuations go, Autolus Therapeutics' Assets plummeted by 2343.44% in 2023, and later skyrocketed by 10851.48% in 2024.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Assets stood at $405.6 million in 2021, then rose by 20.89% to $490.3 million in 2022, then dropped by 23.43% to $375.4 million in 2023, then surged by 108.51% to $782.7 million in 2024, then dropped by 15.43% to $661.9 million in 2025.
  • Its Assets was $661.9 million in Q3 2025, compared to $721.0 million in Q2 2025 and $746.3 million in Q1 2025.